Drug Trial Radar · NCT05004311
The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics
Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Sep 27, 2021
Primary completion
Jul 27, 2023
Study completion Aug 10, 2023
Sponsor
- Lead sponsor
- Viatris Innovation GmbHIndustry
- Sponsor type
- Industry
- First posted
- Aug 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To investigate the PK of cenerimod in participants with severe renal impairment as compared to healthy control participants.
Conditions
- Healthy
- Renal Impairment
Interventions
CenerimodDrug
A single oral dose of 0.5 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma concentration-time curve (AUC) from time zero to time t of the last measured concentration above the limit of quantification (AUC0-t) of cenerimodTime frame: Total duration: up to 52 days
- Area under the plasma concentration-time curve (AUC from 0 to infinity) of cenerimodTime frame: Total duration: up to 52 days
- The maximum plasma concentration (Cmax) of cenerimodTime frame: Total duration: up to 52 days
- The time to reach Cmax (tmax) of cenerimodTime frame: Total duration: up to 52 days
- Terminal half-life (t½) of cenerimodTime frame: Total duration: up to 52 days
- Apparent oral clearance (CL/F) of cenerimodTime frame: Total duration: up to 52 days
- Extent of cenerimod protein plasma binding (PPB)Time frame: Total duration: up to 52 days
- Apparent volume of distribution (Vz/F) of cenerimodTime frame: Total duration: up to 52 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
BlueClinical Phase 1 Hospital de Prelado
Porto, Portugal
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.